Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Isr Med Assoc J ; 18(10): 594-599, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28471618

RESUMEN

BACKGROUND: Antibiotic treatment of Clostridium difficile infection (CDI) has a high failure rate. Fecal microbiota transplantation (FMT) has proven very effective in treating these recurrences. OBJECTIVES: To determine which method of fecal microbiota transplantation (upper or lower gastrointestinal) and which type of donor (a relative or unrelated) is superior. METHODS: This is a retrospective analysis of treatment protocols and outcomes in 22 patients with refractory or recurrent CDI who underwent FMT at two Israeli facilities. Each center used a different donor type, stool preparation and method of delivery. The Tel Aviv Sourasky Medical Center used unrelated fecal donors and frozen stool samples and delivered them primarily (92%) via the lower gastrointestinal (GI) tract. Shaare Zedek Medical Center used fresh donor stool of relatives and delivered them primarily (90%) via the upper GI tract. RESULTS: FMT had an overall 2 month cure rate of 89%. Patients treated with FMT that was executed through the lower GI tract recovered faster from the infection (1.6 ± 1.08 vs. 2.4 ± 1 days for the upper tract, P = 0.03). The results also showed that patients who received lower GI tract FMTs were more likely to be cured of CDI (100% vs. 75% for upper tract FMTs, P = 0.16). Five patients (22%) died of CDI/FMT-unrelated causes and two (10%) died of CDI/FMT-related causes during the study period. CONCLUSIONS: Lower GI tract FMT is a safe and effective treatment for refractory and recurrent CDI, and yields quicker results than upper GI tract FMT.


Asunto(s)
Clostridioides difficile/aislamiento & purificación , Infecciones por Clostridium/terapia , Trasplante de Microbiota Fecal/métodos , Tracto Gastrointestinal/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Infecciones por Clostridium/mortalidad , Selección de Donante , Trasplante de Microbiota Fecal/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Israel , Masculino , Persona de Mediana Edad , Recurrencia , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
2.
Isr Med Assoc J ; 17(8): 510-4, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-26394495

RESUMEN

Clostridium difficile-associated diarrhea is a problem most hospital-based physicians will face in their career. This review aims to refresh current knowledge with regard to Clostridium difficile infection and bring physicians up to date with the latest developments in the growing field of fecal microbiota transplantation, the benefits it offers, and the promise this and other developments hold for the future.


Asunto(s)
Enterocolitis Seudomembranosa , Heces/microbiología , Tracto Gastrointestinal , Microbiota , Trasplantes/microbiología , Antibacterianos/efectos adversos , Clostridioides difficile/aislamiento & purificación , Enterocolitis Seudomembranosa/etiología , Enterocolitis Seudomembranosa/microbiología , Enterocolitis Seudomembranosa/terapia , Tracto Gastrointestinal/microbiología , Tracto Gastrointestinal/fisiopatología , Humanos , Microbiota/efectos de los fármacos , Microbiota/fisiología , Evaluación de Resultado en la Atención de Salud
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...